Click here for a video of a webinar from March 22, 2020 on Active Surveillance with a urologist and 2 patients.
November 2019 Awareness Night Active Surveillance Decisions (Why, Who, How, and When you know it’s time to be treated) Dr. Danny Vesprini, MD, MSc, FRCPC Affiliate Scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute Radiation Oncologist, Dept. of Radiation Oncology, Sunnybrook Odette Cancer Centre Asst. Prof., Dept. of Radiation Oncology, U. of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 1:04:57 minutes <
Noted urologic surgeon Bert Vorstman, MD, MS, FAAP, FRACS, FACS today has issued a stinging report regarding the unreliable PSA test, the mislabeling of the common Gleason 6 prostate disease as a cancer, and the misrepresentation that the radical (robotic) prostatectomy treatment is scientifically proven to be safe and effective – a charade that represents an outrageous and shameful trifecta of abominations. Read the article.
Data from the survival outcomes of patients support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease. Read the article here.